person · Reporting owner
McClellan Michael James
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | EVP, Chief Financial Officer | November 05, 2019 | November 06, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date November 05, 2019 · Filed November 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 15,898.272 |
Last balance in matching sequence
After 2019-11-05 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2019-11-05 · Exercise / conversion · Acquired 695 · Balance 16,140.272 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Row 2 · 2019-11-05 · Sale · Disposed 242 · Balance 15,898.272 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.83 to $8.835, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-11-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-05 · Exercise / conversion · Disposed 695 · Balance 0 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6: Restricted share units were granted on November 5, 2015, with 695 having vested on each of November 5, 2018 and November 5, 2019. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.83 to $8.835, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6: Restricted share units were granted on November 5, 2015, with 695 having vested on each of November 5, 2018 and November 5, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 05, 2019 Filed Nov 6, 2019 11:46 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 695 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-055414 · doc4.xml · derivative · entry 3 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 695 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on November 5, 2015, with 695 having vested on each of November 5, 2018 and November 5, 2019. F6 · derivative.expiration_date: Restricted share units were granted on November 5, 2015, with 695 having vested on each of November 5, 2018 and November 5, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| November 05, 2019 Filed Nov 6, 2019 11:46 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 242 | $8.83 | $2,137.85 |
DisclosureSEC source: 0001209191-19-055414 · doc4.xml · nonDerivative · entry 2 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,898.272 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.83 to $8.835, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 05, 2019 Filed Nov 6, 2019 11:46 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 695 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-055414 · doc4.xml · nonDerivative · entry 1 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,140.272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 11:17 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 4,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-050264 · doc4.xml · derivative · entry 3 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,091 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on September 18, 2017 and vested on September 18, 2019. F6 · derivative.expiration_date: Restricted share units were granted on September 18, 2017 and vested on September 18, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 11:17 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,406 | $7.83 | $11,010.81 |
DisclosureSEC source: 0001209191-19-050264 · doc4.xml · nonDerivative · entry 2 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,445.272 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.82 to $7.835, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 11:17 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 4,091 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-050264 · doc4.xml · nonDerivative · entry 1 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,851.272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 18, 2019 Filed Mar 19, 2019 12:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 230 | $16.63 | $3,823.77 |
DisclosureSEC source: 0001209191-19-020159 · doc4.xml · nonDerivative · entry 2 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,760.272 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.5800 to $16.6800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2019 Filed Mar 19, 2019 12:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 660 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-020159 · doc4.xml · derivative · entry 3 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 661 Underlying: Ordinary Shares · 660 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 17, 2016, with 660 vesting on each of March 17, 2018 and March 17, 2019 and 661 vesting on Mach 17, 2020. F6 · derivative.expiration_date: Restricted share units were granted on March 17, 2016, with 660 vesting on each of March 17, 2018 and March 17, 2019 and 661 vesting on Mach 17, 2020. Read SEC document |
| March 17, 2019 Filed Mar 19, 2019 12:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 660 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-020159 · doc4.xml · nonDerivative · entry 1 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,990.272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 12:28 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 363 | $16.88 | $6,128.64 |
DisclosureSEC source: 0001209191-19-016089 · doc4.xml · nonDerivative · entry 2 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,330.272 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.755 to $17.130, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 12:18 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 50,746 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-017232 · doc4.xml · derivative · entry 1 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,746 Underlying: Ordinary Shares · 50,746 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 16,915 vesting on each of March 4, 2021 and March 4, 2022 and 16,916 vesting on March 4, 2023. F2 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 16,915 vesting on each of March 4, 2021 and March 4, 2022 and 16,916 vesting on March 4, 2023. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2019 Filed Mar 5, 2019 12:28 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,049 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016089 · doc4.xml · derivative · entry 3 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,099 Underlying: Ordinary Shares · 1,049 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 1,049 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,050 vesting on Mach 3, 2021. F6 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 1,049 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,050 vesting on Mach 3, 2021. Read SEC document |
| March 03, 2019 Filed Mar 5, 2019 12:28 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,049 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-016089 · doc4.xml · nonDerivative · entry 1 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,693.272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 11:38 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 695 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-057493 · doc4.xml · derivative · entry 3 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 695 Underlying: Ordinary Shares · 695 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on November 5, 2015, with 695 vesting on each of November 5, 2018 and November 5, 2019. F5 · derivative.expiration_date: Restricted share units were granted on November 5, 2015, with 695 vesting on each of November 5, 2018 and November 5, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 11:38 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 346 | $22.73 | $7,865.13 |
DisclosureSEC source: 0001209191-18-057493 · doc4.xml · nonDerivative · entry 2 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,644.272 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.73 to $22.7338, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 11:38 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 695 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-057493 · doc4.xml · nonDerivative · entry 1 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,990.272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 20:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 287 | $17.88 | $5,130.99 |
DisclosureSEC source: 0001209191-18-020861 · doc4.xml · nonDerivative · entry 2 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,295.272 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.83 to $17.925, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2018 Filed Mar 20, 2018 20:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 660 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-020861 · doc4.xml · derivative · entry 3 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,321 Underlying: Ordinary Shares · 660 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 17, 2016, with 660 vesting on each of March 17, 2018 and March 17, 2019 and 661 vesting on Mach 17, 2020. F5 · derivative.expiration_date: Restricted share units were granted on March 17, 2016, with 660 vesting on each of March 17, 2018 and March 17, 2019 and 661 vesting on Mach 17, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 17, 2018 Filed Mar 20, 2018 20:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 660 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-020861 · doc4.xml · nonDerivative · entry 1 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,582.272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 21:16 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Tax withholdingOrdinary Shares | 455 | $19.38 | $8,817.90 |
DisclosureSEC source: 0001209191-18-017216 · doc4.xml · nonDerivative · entry 2 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,922.272 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2018 Filed Mar 6, 2018 21:16 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,049 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017216 · doc4.xml · derivative · entry 3 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,148 Underlying: Ordinary Shares · 1,049 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 1,049 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,050 vesting on Mach 3, 2021. F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 1,049 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,050 vesting on Mach 3, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2018 Filed Mar 6, 2018 21:16 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,049 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-017216 · doc4.xml · nonDerivative · entry 1 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,377.272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:22 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 48,361 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009192 · doc4.xml · derivative · entry 2 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,361 Underlying: Ordinary Shares · 48,361 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022. F4 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:22 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantStock Options (right to buy) · Derivative | 123,288 | $0.00 Strike: $18.61 | $0.00 |
DisclosureSEC source: 0001209191-18-009192 · doc4.xml · derivative · entry 1 McClellan Michael James · CIK 0001721544 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,288 Underlying: Ordinary Shares · 123,288 shares Expires 2028-02-08 F1 · derivative.exercise_date: Stock options were granted on February 9, 2018, with 41,096 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.